Jason Matuszewski, Chief Executive Officer and Director of BioStem Technologies, Inc. (NASDAQ:BSEM), filed a Form 4 on November 19, 2026, disclosing a sale of 14,300 shares of common stock on November 17, 2026, executed to cover tax obligations related to the exercise of vested options.
Key Highlights
- Sale transaction: Matuszewski disposed of 14,300 shares of BioStem Technologies common stock on November 17, 2026, at a price of $1 per share.
- Purpose of sale: According to the filing, the shares were sold to cover the reporting person's tax obligation in connection with the exercise of vested options.
- Remaining direct ownership: Following the transaction, Matuszewski directly holds 1,539,251 shares of common stock.
- Option holdings: Matuszewski holds options to purchase common stock across four grants, with exercise prices of $2, $10.05 (two separate grants), and $5.5, covering 2,000,000, 198,807, 40,427, and 440,529 shares respectively.
- Restricted stock units: The filing reports three separate RSU grants covering 33,874, 99,901, and 363,636 shares of common stock, each representing a contingent right to receive one share of common stock.
- Roles reported: Matuszewski is identified in the filing as Director, 10% Owner, and Chief Executive Officer of BioStem Technologies, Inc.
Jason Matuszewski's November 2026 Share Sale and Derivative Holdings at BioStem Technologies
According to the Form 4 filed on November 19, 2026, Jason Matuszewski sold 14,300 shares of BioStem Technologies, Inc. common stock on November 17, 2026, at $1 per share. The filing states this was a disposition coded "S" and that the shares were sold "to cover the Reporting Person's tax obligation in connection with the exercise of vested options to purchase shares of the Issuer's Common Stock." Following the sale, Matuszewski directly held 1,539,251 shares of common stock.
BioStem Technologies, Inc., traded on NASDAQ under the symbol BSEM and headquartered at 2836 Center Port Circle, Pompano Beach, Florida 33064, is the issuer named in the filing. In addition to common stock, the filing discloses that Matuszewski holds Series A-1 Convertible Preferred Shares, which the filing describes as convertible in whole into shares of common stock on a one-to-one basis at the option of a majority of holders, with no expiration date, covering 100 underlying shares.
The filing also details four stock option grants. The $2 exercise price options covering 2,000,000 shares are described as "fully vested and exercisable." The $10.05 options covering 198,807 shares have a vesting schedule under which 33% vested on March 17, 2026, with the balance vesting in equal quarterly installments over the subsequent two-year period. The $10.05 options covering 40,427 shares follow a similar structure, with the first 33% vesting on October 13, 2026. The $5.5 options covering 440,529 shares are scheduled to begin vesting on February 11, 2027. Three RSU grants covering 33,874, 99,901, and 363,636 shares are also reported, with vesting schedules tied to grant dates of September 15, 2024, March 17, 2025, and February 11, 2026, respectively, as described in the filing's footnotes.
What Was Disclosed
The filing reports a sale of 14,300 BioStem Technologies common shares at $1 per share on November 17, 2026, by CEO Jason Matuszewski, executed to satisfy tax obligations from vested option exercises. The document also sets out Matuszewski's full derivative holdings including options and restricted stock units.



Please wait processing your request...